TRENDING :  Market Movers  |  Top 50   DGAZ (-19.77%)    BTCUSD (%)    AIR (-4.17%)    SHEN (0.34%)    WSM (-1.92%)    AAPL (-3.97%)    A (-3.67%)    FCX (-3.77%)    EXPO (-1.67%)    ETNUSD (%)    ETCUSD (%)    EEM (-1.35%)    DIS (-0.67%)    DGII (-5.99%)    CZZ (-2.4%)    CYCC (-2.73%)    CTB (-1.23%)    COG (0.24%)    CNK (-3.86%)    BZQ (2.58%)    BLL (-1.97%)    BBBY (-1.5%)    BABY (-1.6%)    ANY (16.89%)    AMZN (-5.1%)

 ILMN - Illumina

$301.59 (-5.74%)

Next Earnings



Analyst Rating

CompanyAnalyst NamePT ActionActionRatingTargetDate
BarclaysJack MeehanRaisesMaintainsOverweight$370.0010/24/18
ArgusJasper HellwegRaisesMaintainsBuy$372.0008/10/18
Morgan StanleySteve BeuchawRaisesUpgradesEqual-Weight$320.0008/07/18
CitigroupDaniel AriasRaisesMaintainsBuy$345.0007/31/18
PiperJaffrayWilliam QuirkRaisesMaintainsOverweight$329.0007/17/18
Morgan StanleySteve BeuchawRaisesMaintainsUnderweight$210.0007/13/18
Cowen & Co.RaisesMaintainsOutperform$315.0007/10/18
CitigroupDaniel AriasRaisesMaintainsBuy$330.0006/25/18
Morgan StanleySteve BeuchawRaisesMaintainsUnderweight$195.0005/31/18
Canaccord GenuityMark MassaroRaisesMaintainsBuy$290.0005/29/18
BarclaysJack MeehanUpgradesOverweight$0.0005/07/18
BairdCatherine SchulteRaisesMaintainsOutperform$271.0004/25/18
Morgan StanleySteve BeuchawRaisesMaintainsUnderweight$170.0004/11/18
CitigroupDaniel AriasRaisesMaintainsBuy$275.0002/06/18
First AnalysisUpgradesOverweight$0.0001/31/18
BTIG ResearchInitiates Coverage OnNeutral$0.0001/05/18
Evercore ISI GroupRoss MukenAnnouncesInitiates Coverage OnOutperform$250.0001/04/18
Wells FargoTim EvansUpgradesOutperform$0.0001/02/18
Morgan StanleySteve BeuchawRaisesMaintainsUnderweight$135.0012/14/17


No recommendations found.
Service NameTrader NameStrategy% ReturnIssue Date
TopFlight Trades - Premium (Options)Eric CunninghamBuy Calls-93.43 %09/24/18View

This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.



3 Healthcare Stocks That Have a Killer Advantage

Some stocks just have it What is it A killer advantage that makes them dominant in their industry Three healthcare stocks that definitely enjoy such an advantage are Illumina NASDAQ ILMN Intuitive Surgical NASDAQ ISRG and Teladoc Health NYSE TDOC Here

Better Buy: EXACT Sciences Corporation vs. Illumina

Healthcare products remain in demand in good times and in bad That s a big reason the sector is a great place for investors to hunt for stock ideas In today s matchup we re pitting cancer detection specialist EXACT Sciences Corporation NASDAQ EXAS against DNA sequencing

Nasdaq 100 Movers: NVDA, ALGN

In early trading on Friday shares of Align Technology topped the list of the day s best performing components of the Nasdaq 100 index trading up 2 0 Year to date Align Technology registers a 2 2 gain And the worst performing Nasdaq 100 component thus far on the day is NVIDIA

IBB, GILD, CELG, ILMN: ETF Outflow Alert

Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the iShares Nasdaq Biotechnology ETF Symbol IBB where we have detected an approximate 99 1 million dollar outflow that s a 1 2 decrease week over week

Pacific Biosciences Offers Insights on Aedes aegypti Genome

Pacific Biosciences of California Inc PACB announced that it has published exclusive insights on the highest quality genome assembly for the Aedes aegypti mosquito in a journal called Nature While the process was initiated by researchers of the Rockefeller University and other

Illumina (ILMN) Dips More Than Broader Markets: What You Should Know

In the latest trading session Illumina ILMN closed at 308 23 marking a 0 95 move from the previous day This move lagged the S amp P 500 s daily loss of 0 76 Meanwhile the Dow lost 0 82 and the Nasdaq a tech heavy index lost 0 9 Prior to today s trading shares of the

Is This the Real Reason Illumina Acquired Pacific Biosciences?

In a somewhat surprising development Illumina NASDAQ ILMN recently announced its intention to acquire leading rival Pacific Biosciences NASDAQ PACB for 1 2 billion The move will combine the two leading DNA sequencing approaches address a technology weakness in Illumina

Here's Why Illumina's $1.2 Billion Acquisition Makes Sense

When a company announces it is making an acquisition and paying double what the target s share price was just the week before it would be natural to question whether the acquirer is really getting much of a bargain But when Illumina NASDAQ ILMN announced it was acquiring

3 DNA Stocks That Are on the Uptrend

InvestorPlace Stock Market News Stock Advice amp Trading Tips The future of genetic medicine and DNA stocks is extremely bullish over the long term But as is normal of any emerging technology there will be plenty of bumps along the road The good news is that those bumps will

Is Illumina (ILMN) a Great Growth Stock?

Growth stocks can be some of the most exciting picks in the market as these high flyers can captivate investors attention and produce big gains as well However they can also lead on the downside when the growth story is over so it is important to find companies which are still seeing

Here's My Top Stock to Buy in November

Have you ever seen a kid in a candy store That s how I felt as the stock market fell in recent weeks Skittish investors were making lots of stocks that I really liked available at discounted prices So I bought and bought and bought Over a three week period I added seven new

3 Growth Stocks Healthcare Investors Should Buy Now

The potential to revolutionize healthcare offers investors a significant opportunity to profit from buying top stocks While there are many healthcare stocks that growth investors can consider I suggest looking at Illumina NASDAQ ILMN Centene Corp NYSE CNC and

The Zacks Analyst Blog Highlights: DXP Enterprises, Bristol-Myers Squibb, EnPro Industries, Illumina and NetApp

For Immediate Release Chicago IL November 9 2018 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog include

Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A

Millions of Americans suffer from depression and there s a big unmet need for new depression drugs because about one third of patients don t respond adequately to existing treatment options To fill that need Alkermes NASDAQ ALKS developed ALKS 5461 a once daily pill

Is Illumina (ILMN) Outperforming Other Medical Stocks This Year?

Investors focused on the Medical space have likely heard of Illumina ILMN but is the stock performing well in comparison to the rest of its sector peers Let s take a closer look at the stock s year to date performance to find out Illumina is a member of our Medical group which includes

Illumina To Acquire Pacific Biosciences At $8.00/shr - Quick Facts

Illumina To Acquire Pacific Biosciences At $8.00/shr - Quick Facts

Illumina Inc. Q3 adjusted earnings Beat Estimates

Illumina Inc. Q3 adjusted earnings Beat Estimates

Illumina Q3 18 Earnings Conference Call At 5:00 PM ET

Illumina Q3 18 Earnings Conference Call At 5:00 PM ET